Document:

EX-4.5.1

 CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A.—CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED
AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION. 
 Amendment to the Product Development, Option, License and Commercialization
Agreement 
 This Amendment to the Product Development, Option, License and Commercialization Agreement shall become effective as of the 18th of November 2015 (hereinafter the “Effective Date”) by and between Les Laboratoires Servier, a corporation incorporated under the laws of France having a principal place of business
at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and lnstitut de Recherches lnternationales Servier, a corporation incorporated under the laws of France having its principal place of business at 50 rue Carnot, 92 150 Suresnes,
France (“IRIS”) (LLS and IRIS being together referred to as “Servier”), and Cellectis SA, a company incorporated under the laws of France having a principal place of business, at 8, rue de la Croix Jarry, 75013
Paris, France (“Cellectis”). Cellectis and Servier are individually referred to herein as a “Party” and collectively, as the “Parties.” 

 

	I.	CONTEXT 

 Servier and Cellectis share a common objective consisting in the strategic optimization of the
global development of the Cellectis CAR technology on the targets identified as per the terms of that certain Product Development, Option, License and Commercialization Agreement effective as of February 7, 2014 entered into between the parties
thereto (the “Agreement”). Unless otherwise specifically provided in this amendment (the “Amendment”), capitalized terms shall have the meaning ascribed thereto in the Agreement. 

Servier contemplates entering into an exclusive sub-license agreement with a third party partner (the “US Partner”) for the development and
commercialization of UCART19 Products and UCART [***] Products in the United States of America and its territories and possessions (the “US Sublicense”). 

Servier and Cellectis are willing to amend the Agreement with respect to UCART19 Candidate Products and UCART [***] Candidate Products in order to
(i) include terms and conditions for development of additional UCART19 Candidate Products and [***] Candidate Products, (ii) allow an early exercise of the Option to License by Servier, as per the terms of article 6.2 of the Agreement, for
the first UCART19 Candidate Product Developed by Cellectis under the Agreement (the “UCART19 Product V1”), and (iii) allow an early exercise of the Option to License by Servier, as per the terms of article 6.2 of the Agreement,
for UCART [***] Candidate Products and additional UCART19 Candidate Products upon achievement of their first validated GMP batch and subject to the validation by Servier of the corresponding IND or IMPD Enabling Data Package. For the avoidance of
doubt, should Servier not validate an IND or IMPD Enabling Data Package, as appropriate, or not exercise the corresponding Option to License, then the terms of the article 4.1 (c) of the Agreement shall apply to the corresponding Candidate
Product. 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	1	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

 For purposes of this Amendment, “IND or IMPD Enabling Data Package” shall mean: [***]. 

 

	II.	AMENDMENT ENTRY INTO FORCE 

 The Amendment shall enter into force as of the Effective Date. 

The Parties hereby agree to issue, within four days following the Effective Date, with the US Partner the joint press release relating to the transactions
contemplated herein attached as Exhibit B. 
  

	III	GRANT OF RIGHTS 

  

	 	a)	Subject to the entry into force of the Amendment, Cellectis hereby grants to Servier a license for the UCART19 Product as per the terms of the Agreement, except for the TAL nuclease Cellectis Patents for which the
license grant is: 

  

	 	(i)	subject to the terms and conditions of the Agreement, Cellectis grants to Servier, on a country by country basis, the right to use the TAL nucleases engineered by Cellectis pursuant to this Agreement to develop the
UCART19 Product V1 until the filing of the corresponding IND or IMPD (or foreign equivalent); 

  

	 	(ii)	after the IND or IMPD filing, subject to the terms and conditions of the Agreement, Cellectis grants to Servier, on a country by country basis, an exclusive license on the TAL nuclease Cellectis Patent, to use the TAL
nucleases engineered by Cellectis to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, and otherwise exploit the UCART19 Product V1, with the right to grant sublicense as provided in the
Agreement. 

  

	 	b)	Subject to the entry into force of the Amendment, and (i) upon achievement of its first validated GMP batch and (ii) subject to the validation by Servier of the corresponding IND or IMPD Enabling Data Package
and exercise of the corresponding Option to License, Cellectis will grant to Servier a license on a Product by Product basis for the additional UCART19 Candidate Products and UCART [***] Candidate Products (as identified in the Development Plan
attached hereto as Exhibit C) as per the terms of the Agreement, except for the TAL nuclease Cellectis Patents for which the license grant will be the same as the rights granted to Servier under section (a) (i) and (ii) of this
Article 3 of the Amendment. 

  

	IV.	TECHNOLOGY TRANSFER / TRANSFER OF KNOW-HOW 

 1. With respect to UCART19 Product, Cellectis shall
regularly inform Servier in advance of each material step of [***] and promptly notify Servier of any difficulties or delays as well as of Cellectis’ reasonable efforts to mitigate such difficulties or delays. Cellectis shall respond to any
reasonable request from Servier in connection with performance of such [***]. 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	2	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

 Prior to the entry into force of this Amendment, Cellectis has provided to Servier (i) [***] (the
“CMO Terms”). [***]. 
 2. Article 5.2 paragraph 2 shall be modified as follow: 

 

	–	replace “Servier may elect at any time before entering into the first Phase II studies (or during the performance of the Phase II studies) to have the manufacture of the Products transferred by Cellectis or its
designee, at Servier’s costs, to a Contract Manufacturing Organization selected by Servier and reasonably acceptable to Cellectis” by “Servier may elect at any time before entering into the first Phase II studies but after the
exercise of the corresponding Option to License for any Product, to have the manufacture of such Products transferred by Cellectis or its designee, at Servier’s costs, to Servier, its US Partner or its Designee reasonably acceptable to
Cellectis”. 

 For sake of clarity, Cellectis (or its designee, under Cellectis’ responsibility) shall use
diligent efforts to perform the technology transfer to Servier, its US Partner or its Designee necessary for Servier to conduct the manufacturing of each Product. Such technology transfer will be made on a Product-by-Product basis (provided that
once such technology transfer has been made for a Product, it is deemed to be made for any subsequent Products, Follow-on Products and Backup Products directed against the same Target to the extent that in such case and if the manufacturing of such
subsequent Product, Follow-on Products and Backup Products requires additional technology transfer due to subsequent changes, Cellectis shall use its Commercially Reasonable Efforts to provide reasonable support to Servier, its US Partner or its
Designee with respect to such technology transfer), and will start at Cellectis’ discretion within [***] following: 
  

	 	(i)	election by Servier to have the manufacture of the Products transferred by Cellectis or its designee, at Servier’s costs, to Servier or its Designee. ; 

 

	 	(ii)	sending by Servier to Cellectis of a written waiver of Servier’s rights under Section 5.2 paragraph 1 to request Cellectis to manufacture or have manufactured such Product and subsequent Product, Follow-on and
Backup Product directed against the same Target (under conditions specified above) until the end of Phase II, such waiver will nonetheless be effective only once the technology transfer will be successfully and timely completed. 

Upon request of Servier and subject to (ii) above, Cellectis shall initiate the technology transfer for manufacture of UCART19 Product V1 to Servier or
its Designee during [***]. 
  

	V.	OPTIONS EXERCISE 

  

	A.	UCART19 Product 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	3	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

 1. Concurrently with the entry into force of the Amendment, Servier does hereby exercise its Option to License
the UCART19 Product V1, according to the terms of the Agreement and this Amendment, and Cellectis does hereby acknowledge the exercise of such Option to License. The payments by Servier under Section VI.1 (a) of the Amendment shall be made in
accordance with the terms provided therein. 
 2. Without prejudice of Sections 3.5 and 4.2 (c) of the Agreement and subject to the availability of
UCART19 Product V1 in sufficient quantities and the obtention of the necessary authorizations to conduct the below mentioned Phases I clinical trials, Servier commits to conduct or have conducted in [***] for UCART19 V1, provided that
(i) Servier shall use commercially reasonable efforts to start in [***] the [***], and (ii) the pediatric Phase I clinical trial shall be conducted at Great Ormond Street Hospital (London, UK). 

Notwithstanding the exercise of the Option to License by Servier, Cellectis will perform, in its own name and in consultation with Servier, the filing of the
Clinical Trial Applications in the [***] for the first Phases I of UCART19 V1, and will use its Commercially Reasonable Efforts to perform such filings no later [***]. For sake of clarity, Cellectis will be entitled to make any press release on such
filings pursuant to Section 8.6 of the Agreement provided, however, that (i) Cellectis will provide Servier with any such draft press release within five (5) days prior to its public disclosure and (ii) Servier’s right to
make comments on any such draft press release shall be limited to two (2) days following receipt of the corresponding draft from Cellectis. Following the filing of the Clinical Trial Application referred to above, the responsibility to conduct
the Phase I studies related to the UCART19 Product V1 will be transferred to Servier or its Designee, which shall then become the sponsor of such Phase 1 studies. Cellectis will cooperate with Servier in connection with such transfer as provided in
Section 5.1 of the Agreement. 
 Servier shall regularly inform Cellectis of the progress of the Studies and respond to any reasonable request from
Cellectis in connection with the performance of [***] Phase 1 study. With respect to [***] Phase 1 study, Servier will copy Cellectis [***] and will provide Cellectis on an ongoing basis with [***] will provide Cellectis through the JRDC members
[***]. The information obligation contained in the preceding sentence shall also apply with respect to other UCART19 Products, Follow-on Products or Backup Products (including UCART19 V2) and the UCART [***] Products, Follow-on Products or Backup
Products (including the [***] Products) if and when the corresponding Option to License is exercised by Servier pursuant to the Agreement. Servier will provide to Cellectis the [***]. Cellectis may communicate material results related to UCART19
Product V1 (including without limitation such intermediate results) as well as on any compassionate uses of UCART 19, subject to Servier’s prior prompt written approval as to the form and content of such communication, which approval will not
be unreasonably withheld or delayed. 
 3. The exercise of the Option to License for the UCART19 Product V1 shall not relieve either Party’s obligation
regarding the development of such UCART19 Product V1, and the payments related thereto, and in particular: 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	4	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

	 	(i)	Section 5.1 of the Agreement, to the extent necessary for Servier to conduct its activities as contemplated in this Amendment. 

In particular, Cellectis shall provide Servier with the relevant documentation in Cellectis’ possession reasonably necessary for Servier
to conduct the Phases 1 of UCART19; 
  

	 	(ii)	the supply by Cellectis, at its own costs, of the clinical supplies of UCART19 Product V1 to Servier for the first Phase 1 [***] study which is limited to amounts necessary [***]: 

 

	 	•	 	[***] 

  

	 	•	 	[***] 

  

	 	•	 	[***] 

  

	 	(iii)	subject to the specific conditions set forth below, the payment by Servier of the royalties and milestones under Sections 6.3(a) to (g), 6.4, and 6.5 of the Agreement; and 

 

	 	(iv)	the supply by Cellectis, at Servier’s costs, of the clinical supplies of UCART19 Product V1 for the Phase 1 [***] study. 

  

	 	(v)	if requested by Servier, Cellectis shall use its Commercially Reasonable Efforts to develop one or more additional UCART19 Candidate Products. The related Option to License shall be exercisable as of: 

 

	 	(a)	the validation by Servier of the corresponding IND or IMPD Enabling Data Package submitted by Cellectis (provided that upon reception by Servier of an IND or IMPD Enabling Data Package for a Candidate Product, Servier
shall have [***] to validate or not the IND or IMPD Enabling Data Package), and 

  

	 	(b)	the provision of the first validated GMP batch for such Candidate Product. 

 The provisions of
Section 4.1 of the Agreement shall apply mutatis mutandis. For the avoidance of doubt, should Servier not validate an IND or IMPD Enabling Data Package, as appropriate, or does not exercise the corresponding Option to License within the
timelines described in Section 4.1 (b), then the terms of the article 4.1 (c) of the Agreement shall apply to the corresponding Candidate Product. 

Cellectis acknowledges and agrees that Servier has requested the development by Cellectis of the second UCART19 Product (the “UCART19
V2”) as set forth in the Development Plans on Exhibit C hereto. Cellectis agrees to generate data up 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	5	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

 
to an IND or IMPD Enabling Data Package for such UCART19 V2 in accordance with and on the timelines set forth in Exhibit C. The Parties further acknowledge and agree that Servier and its
US Partner may conduct research and development work on UCART19 V2 before the exercise of the Option to License. UCART19 V2 shall be treated as a Follow-On Product, unless the development of the lead UCART19 Product is ceased prior to the
Commercialization stage, in which case such UCART19 V2 will become a lead product and the subsequent milestones for such product shall be payable at 100% instead of 50%. Additional UCART19 Product(s) will either be treated as new Pre-Candidate
Product(s), new Candidate Product(s), Follow-on Product(s) or Back-up Product(s), as per Sections 3.3 and 3.4 of the Agreement. 
 4. Article
3.1 of the Agreement shall be amended in its entirety as follows: 
 “3.1 Development of UCART 19 Product 

Subject to Article 5.2 relating to Manufacturing aspects, Servier shall be responsible for conducting the Development of each UCART19 Product after the
exercise of the Option to License. Upon Servier’s request, Cellectis shall make reasonable efforts to assist Servier in the conduct of the part of the Development of the UCART19 Product towards the completion of the first Phase 1.”

  

	B.	UCART [***] Products 

 1. The Option to License with respect to each UCART [***] Candidate Product shall
be exercisable as of: 
  

	 	(a)	the validation by Servier of the IND or IMPD Enabling Data Package submitted by Cellectis (provided that upon reception by Servier of an IND or IMPD Enabling Data Package for a Candidate Product, Servier shall have
[***], to validate or not the IND or IMPD Enabling Data Package), and 

  

	 	(b)	the provision of the first validated GMP batch. 

 The provisions of Section 4.1 of the Agreement shall
apply mutatis mutandis. For the avoidance of doubt, should Servier not validate an IND or IMPD Enabling Data Package, as appropriate, or does not exercise the corresponding Option to License within the timelines described in Section 4.1 (b),
then the terms of the article 4.1 (c) of the Agreement shall apply to the corresponding Candidate Product. 
 2. Cellectis will use its
Commercially Reasonable Efforts to initially generate data up to an IND or IMPD Enabling Data Package for [***] UCART [***] Candidate Product(s) pursuant to the Development Plan attached as Exhibit C. For the sake of clarity, Cellectis would
not be responsible for the filing of the IND and/or the IMPD (or any other foreign equivalent), which shall be filed by Servier or its Designee. 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	6	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

 3. The exercise of the Option to License for [***] UCART [***] Candidate Product shall not relieve either
Party’s obligation regarding the development of such UCART [***] Candidate Product, and the payments related thereto, and in particular: 
  

	 	(i)	Section 5.1 of the Agreement, to the extent necessary for Servier to conduct its activities as contemplated in this Amendment; 

  

	 	(ii)	its development by Cellectis until completion and delivery to Servier of an IND or IMPD Enabling Data Package for one or more UCART [***] Candidate Products. In this respect, the Parties acknowledge and agree that
Servier’s intent is to request an IND or IMPD Enabling Data Package for [***] UCART [***] Products, [***]. In the event Servier decides to exercise its Option to License on such [***] UCART [***] Products, the [***] UCART [***] Product shall be
treated as a new Product and the subsequent milestones for such Product shall be payable at 100%; 

  

	 	(iii)	subject to the specific conditions set forth below, the payments by Servier to Cellectis of the milestone “[***]” corresponding to a milestone payment of [***], and any and all milestones and royalties under
Sections 6.3 (b) to (g), 6.4 and 6.5 of the Agreement; 

  

	 	(iv)	Cellectis shall continue to be responsible, at Servier costs, for the supply to Servier of UCART [***] Products for use in the first Phase 1 study, as contemplated in the Development Plan attached hereto as Exhibit C.

 4. Article 3.3 of the Agreement shall be amended as follows: 

“3.3. Development of the Pre-Candidate Product(s) and Candidate Products up to IND/IMPD Enabling Data Package. 

Following identification and selection of each Pre-Candidate Product and Candidate Product, Cellectis shall be responsible for conducting the Development
activities of the corresponding Pre-Candidate Product and Candidate Product until completion and delivery by Cellectis to Servier of an IND or IMPD Enabling Data Package, in accordance with the corresponding Development Plan as defined by the JRDC
and validated by the JSC. Servier and Cellectis shall cooperate closely in such Development. For sake of clarity, for any Development of a Pre-Candidate Product and Candidate Product not initially planned in the Development Plan, the Parties shall
meet in order to define the technical and financial conditions for such additional Development. For any Development of a UCART 19 or UCART [***] Pre-Candidate Product and Candidate Product not initially planned in the Development Plan attached
hereto as Exhibit C, the Parties shall meet in order to define the technical and financial conditions for such additional Development”. 
 5.
In Article 4.1 (b) of the Agreement, for UCART19 Candidate Products and UCART [***] Candidate Products, the reference to “Phase 1 Data Package” shall be replaced by “IND or IMPD Enabling Data Package”. 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	7	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

 6. The Parties further acknowledge and agree that Servier and its US Partner may conduct research work on UCART
[***] Pre-Candidate Products and UCART [***] Candidate Products before the exercise of the Option to License, provided that all intellectual property generated in connection therewith that is owned by Servier and/or its US Partner specifically and
solely related to the UCART [***] Pre-Candidate Products and/or the UCART [***] Candidate Products will form part of the Servier IP to be licensed to Cellectis in the absence of exercise of the Option to License pursuant to Section 4.1
(c) of the Agreement. Servier and/or its US Partner which is responsible for the filing of such intellectual property shall cooperate as regards the preparation, filing, prosecution and maintenance of all such patent rights worldwide and shall
in particular inform and discuss with Cellectis in due time the patent strategy and of any material correspondence received and draft correspondence to be exchanged with the patent offices. Servier or its US Partner which is responsible for the
filing of such intellectual property shall take into good faith consideration any Cellectis’ proposal or comment. Cellectis will, and Servier or its US Partner will no longer, be responsible for preparation, filing, prosecution and maintenance
of all such patent rights if such patent rights are licensed to Cellectis in the absence of exercise of the Option to License pursuant to Section 4.1 (c) of the Agreement. 

Should Servier or its US Partner develop any improvement to the Platform Patents (as defined in Section VII.A.1. of this Amendment) that is generated in the
performance of the activities conducted pursuant to V.B.6 above, Servier will grant to Cellectis a worldwide, fully paid-up, royalty free, sublicensable, co-exclusive (together with Servier and its sublicensees (including the US Partner) for the
performance of their rights and obligations under the Agreement and the US Sublicense) license under such improvement to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise
exploit and commercialize products and process. 
 Servier shall cause its US Partner to comply with the provisions of this section V.B.6. 

 

	VI.	SPECIFIC FINANCIAL TERMS ON UCART19 and UCART [***] CANDIDATE PRODUCT 

  

	1.	Payments 

  

	 	a)	Upfront Payments. Upon entry into force of this Amendment, Servier shall pay to Cellectis the following amounts within [***] of receipt of the corresponding invoice: 

 

	 	•	 	[***]; 

  

	 	•	 	[***]; 

  

	 	•	 	[***]; 

  

	 	•	 	[***]. 

  

	 	b)	Milestones: 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	8	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

	 	•	 	All Milestones Payments due under article 6.3 (a) to (e) of the Agreement for the first UCART19 Product will be fully due by Servier to Cellectis upon achievement of the corresponding Milestone events in
accordance with the Agreement; 

  

	 	•	 	The milestone “[***]” corresponding to a milestone payment of [***], and all Milestone Payments due under article 6.3 (e) of the Agreement for the [***] Product will be fully due by Servier to Cellectis
upon achievement of the corresponding Milestone events in accordance with the Agreement; 

  

	 	•	 	The milestone “[***]” corresponding to a milestone payment of [***], and all Milestone Payments due under article 6.3 (e) of the Agreement applicable to Follow-on Products for the second UCART19 Product
will be fully due by Servier to Cellectis upon achievement of the corresponding Milestone events in accordance with the Agreement. For the avoidance of doubt, the first between UCART19 Product V1 and UCART19 V2 that reach the applicable milestones
under article 6.3 (e) shall bear 100% of such milestone payments and the second shall bear 50% of such milestone payments; 

  

	 	•	 	The milestone “[***]” corresponding to a milestone payment of [***], and all Milestone Payments due under article 6.3 (e) of the Agreement for the [***] Product will be fully due by Servier to Cellectis
upon achievement of the corresponding Milestone events in accordance with the Agreement ; 

  

	 	•	 	An additional milestone of [***] US dollars ([***]) will be fully due by Servier to Cellectis upon achievement of the milestone “[***]”, for the [***] Product; 

 

	 	•	 	An additional milestone of [***] will be fully due by Servier to Cellectis upon achievement of the milestone “[***]” for the first UCART 19 Product; 

 

	 	•	 	For sake of clarity, any and all payments due under 6.4 and 6.5 are due for UCART19 Products and Follow-on Products and [***] Products; 

 

	 	•	 	Payments due under article 6.3 (g) of the Agreement as amended below for UCART19 Products and Follow-on Products and [***] Products will be fully due by Servier to Cellectis subject to payment by the US Partner to
Servier. 

  

	 	c)	Reimbursement of costs incurred by Cellectis: 

  

	 	•	 	 In consideration of the work performed by Cellectis relating to the development of the [***] Candidate Products and the second UCART19 Candidate
Product up to the final delivery of the IND/IMPD Enabling Data Package, Servier will pay Cellectis on a full time equivalent basis (the FTE rate of which will be [***] with respect to [***], upon submission of a quarterly invoice together with all
supporting documentation with respect to the costs incurred. The FTE rate shall be adjusted annually on each 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	9	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

	 	 
anniversary date of the Amendment by an amount equal to the percentage increase for the last quarter preceding such anniversary date of the [***]. The costs incurred by Cellectis relating to the
development of the [***] Candidate Product for the “[***]” from the achievement of the last milestone paid by Servier related to the [***] Candidate Product up to the effective date of this Amendment amount to [***] in the aggregate and
shall be payable by Servier to Cellectis within [***] of receipt by Servier of the corresponding invoice. 

  

	 	•	 	In consideration of the work performed by Cellectis relating to the filing of the Clinical Trial Applications for UCART19 V1, up to the transfer of the sponsorship as provided in Section V.A.2 of this Amendment, Servier
will reimburse Cellectis the costs incurred by Cellectis [***]. 

  

	 	•	 	As a consequence: 

 the milestone payment due under article 6.3 (a) of the Agreement for
the second UCART19 Candidate Products and the [***] UCART [***] Candidate Products shall no longer apply and will not be due by Servier to Cellectis upon achievement of the corresponding Milestone events, except for the milestone “[***]”
that continue to apply to such Candidate Products and; 
  

	 	d)	Article 6.3 (g) of the Agreement shall be modified to the extent it relates to UCART19 Products and [***] Products so that the words “[***]” shall be replaced by “until [***] on a Product
by Product basis”. 

  

	VII.	GENERAL PROVISIONS 

  

	A.	Intellectual Property and Patent Rights Cooperation 

 1. Article 7.2 (a) shall be revised and
completed as follows: 
 Cellectis’ responsibilities pursuant to Section 7.2 (a) shall continue to apply provided that with respect to
Patents within the Cellectis Patents that cover specifically and solely a Candidate Product or a Product (“Product Patents”), Cellectis remains solely responsible for preparing, filing, prosecuting, and maintaining Product Patents
aiming to cover a Pre-Candidate Product, Candidate Product and/or Product in [***] (“Initial Countries”) at its own costs up to the exercise of the Option to License for the corresponding Candidate Product. For clarity, Cellectis
would seek for patent validation for Pre-Candidate Products and Candidate Products in [***]. 
 Before the exercise of the Option to License, should Servier
wish to have the patent protection of Product Patents extended in territories other than the Initial Countries (the “Additional Countries”), it shall inform Cellectis of its wish, by providing a written notice at least [***] in
advance of the deadline for filing in such Additional Countries, a list of the 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	10	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

 
Additional Countries. Cellectis will then seek patent protection for such requested Additional Countries, provided that Servier shall reimburse Cellectis any reasonable costs and expenses
(including patent attorney costs) incurred by Cellectis in connection with such extension. Cellectis shall further regularly inform Servier in due time with respect to the prosecution actions (including office actions or official actions from patent
offices of such Additional Countries) and any required action in connection with the maintenance of such Cellectis Patents in the Initial Countries and Additional Countries. 

After exercise of the Option to License, with respect to Product Patents, Servier shall have the first right and responsibility at its own cost for preparing,
filing, prosecuting and maintaining all such Patents, provided that Servier shall copy Cellectis on any material correspondence with its intellectual property counsel and consult Cellectis for any draft correspondence to be exchanged with patent
offices. If Servier intends to cease prosecuting any such Patents, it shall inform Cellectis with sufficient advance notice to allow Cellectis to take over such prosecution if Cellectis so wishes. Servier shall not take any actions which can
materially affect the scope, the validity and enforceability of the Product Patents, without Cellectis’ prior written consent. 
 For sake of clarity,
Cellectis remains fully responsible for the Cellectis Patents that does not cover specifically and solely a Pre-Candidate or a Candidate Product (“Platform Patents”), provided that Cellectis shall regularly inform Servier in due
time with respect to the prosecution actions (including office actions or official actions from worldwide patent offices) and any required action in connection with the maintenance of such Platform Patents. 

2. A section 7.2 (d) shall be added as follows: 

“7.2 (d) The Parties shall cooperate as regards the preparation, filing, prosecution and maintenance of the Product Patents worldwide. The filing
Party shall in particular inform the other Party in due time about the patent and about material correspondence received and draft correspondence exchanged with the patent offices. 

Each Party shall take into good faith consideration any other Party’s proposal or comment related to Product Patents.” 

 

	B.	Representation and Warranties 

 [***]. 

 

	C.	Definitions 

 A new definition of “Designee” is included to read as follows: 

“Designee” shall mean a corporation or other entity that is employed by, under contract to, or in partnership with Servier
or an Affiliate thereof, to Develop and/or Commercialize Products in the Territory. 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	11	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

 For clarification purposes, Article 1.6, and 1.44 shall be modified as follows: 

1.6. “Candidate Product” means a product developed by Cellectis as per the Agreement, consisting in an allogeneic anti-tumor adoptive T-cell
expressing a single chain chimeric antigen receptor (CAR) directed against a particular Target including specific Attributes selected by Servier according to Section 3.2 (c). Except for section 6.3, Candidate Product also applies to a Backup
Product and/or a Follow-on Product in case of application of Section 3.4. 
 1.44. “Pre-Candidate Product” means a product developed
by Cellectis as per the Agreement, consisting in an allogeneic anti-tumor adoptive T-cell expressing a single chain chimeric antigen receptor (CAR) directed against a particular Target including specific Attributes. 

 

	D.	US Sublicense 

 Upon Cellectis’ request, Servier shall provide to Cellectis a redacted version of
the part of the US Sublicense containing the development milestones payable, on a Product by Product basis, to Servier by the US Partner until [***]. 
 In
case of termination of the Agreement for Servier breach pursuant to Article 11.2.1 of the Agreement, and at the US Partner’s request, Cellectis agrees to enter into good faith negotiations for a direct license to the US Partner with
respect to UCART19 and [***] Candidate Products or Products on terms substantially similar in scope and grant; provided that (i) the US Sublicense was properly granted in compliance with the terms of this Agreement, and (ii) the US Partner
was in compliance with the terms of such US Sublicense and the applicable provisions of this Agreement. 
  

	E.	Servier Diligence 

 Article 4.2(c) of the Agreement shall be amended as follows: 

“(c) Servier Diligence. Upon Servier’s exercise of the Option to License for a given Product, Servier will use, and will ensure that its
Affiliates, Sublicensees and subcontractors use Commercially Reasonable Efforts in Developing and/or Commercializing the corresponding Product (defined for the purposes hereof as the lead Product, its Follow-On Product(s) and its Backup Product
(s) taken as a whole) in the Targeted Territory. For sake of clarity, UCART 19 Product V1 shall be treated as a lead Product and UCART19 V2 shall be treated as a Follow-On Product of UCART19 Product V1 for the purposes of this Article
4.2(c). For further clarity, the [***] Products shall be treated as [***] lead Products to the extent such Products [***]. The words “in accordance with Section 4.2(c)” shall be added at the end of the first sentence
of Section 3.5 and the word “Product” in Section 3.5 shall be interpreted similarly as in Section 4.2(c). 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	12	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

	F.	Use of data by Cellectis 

 Cellectis shall have the right to use or have used all the data generated by
Cellectis or its subcontractors in the course of the development of the Product Candidates and Products for the development of its own products. 
  

	G.	No other revisions 

 Except as expressly set forth in this Amendment, the other provisions of this
Agreement remain unchanged and continue in full force and effect. 
 To the extent that the provisions of this Amendment conflict with what is set forth in
the Agreement, the provisions of this Amendment shall take precedence. All disputes arising out of or in connection with this Amendment, unless otherwise specified in the Agreement, shall be resolved in accordance with the principles set forth in
article 13.2 of the Agreement. 
 IN WITNESS WHEREOF, the Parties have caused this Amendment to the Product Development, Option, License and
Commercialization Agreement to be executed by their duly authorized representatives. 
 Made in Suresnes, on November 18th, 2015 

 

									
	 For Cellectis SA
	 		 	For Les Laboratoires Servier
					
	 By:
	 	 /s/ André Choulika
	 		 	By:	 	 /s/ Christian Bazantay

	 Name:
	 	 Andre CHOULIKA
	 		 	Name:	 	Christian BAZANTAY
	 Title:
	 	 Chief Executive Officer
	 		 	Title:	 	Proxy
					
		 		 		 	By:	 	 /s/ Eric Falcand

		 		 		 	 Name:
	 	Eric FALCAND
		 		 		 	 Title:
	 	Proxy

  

			
	For Institut de Recherches Internationales Servier
		
	By:	 	 /s/ Emmanuel Canet

	 Name:
	 	Dr Emmanuel CANET
	 Title:
	 	President of R&D

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	13	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

 EXHIBIT A 

IND or IMPD Enabling Data Package 

[***] 
  

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	14	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

 EXHIBIT B 

JOINT PRESS RELEASE 

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell
Therapy for Hematological Malignancies 
 Servier Also Enters Into Exclusive Global License and
Collaboration Agreement with Pfizer to Co-Develop and Commercialize Therapy 
 NEW YORK & SURESNES, France—November 18, 2015:

 Cellectis (Alternext:ALCLS; Nasdaq:CLLS) and Servier today announced that they signed an amendment to their existing collaboration agreement from
February 2014 especially for UCART19, a TALEN® gene-edited allogeneic Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy. Under this amendment, Servier early exercises its option to
acquire the exclusive worldwide rights to further develop and commercialize UCART19, which is about to enter Phase 1 development for chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). 

In addition, Pfizer Inc. (NYSE: PFE) and Servier have entered into an exclusive global license and collaboration agreement to co-develop and commercialize
UCART19. Under the terms of the agreement, Pfizer and Servier will work together on a joint clinical development program for UCART19 and share development costs. Pfizer will be responsible for potential commercialization of UCART19 in the United
States, and Servier will retain marketing rights in countries outside the United States. Pfizer’s collaboration with Servier on UCART19 is distinct from the collaboration with Cellectis that Pfizer announced in June 2014, which did not include
UCART19. 
 UCART19 utilizes Cellectis’ proprietary, allogeneic approach to develop CAR-T therapies that engineer T-cells from non-patient donors for
use in multiple patients. This is different from autologous approaches, which engineer a patient’s own T-cells. 
 Cellectis will receive from Servier
a payment of $38.2 million upon signature. In addition, Cellectis is eligible for over $300 million of milestone payments, R&D financing, and royalties on sales from Servier, based on annual net sales of commercialized products. Financial terms
for the Servier agreement with Pfizer were not disclosed. 
 “Servier’s early option exercise is a strong recognition of the potential value of
UCART19 for patients, as the first allogeneic CAR-T therapy expected to move into clinical development that utilizes Cellectis’ TALEN® gene editing technologies,” said
Dr. André Choulika, Ph.D., chairman and chief executive officer of Cellectis. “Cellectis aims to provide cancer patients with highly innovative best-in-class allogeneic CAR-T therapies across all geographies, and we are proud to
collaborate on this license agreement with Servier and Pfizer to foster access for patients.” 
 “The partnership between Pfizer and Servier is a
major step in the development of UCART19 and our ambition to provide innovative drugs for patients in oncology, as it has been envisioned by Servier’s president, Olivier Laureau,” said Emmanuel Canet, M.D., president, Research and
Development at Servier. 
 “This collaboration on the development of the UCART19 asset builds on Pfizer’s position in the CAR-T space and our
growing portfolio of investigational immuno-oncology assets, which is a major priority for our oncology business,” said Mikael Dolsten, M.D., Ph.D., president, Worldwide Research and Development at Pfizer. “This work with Servier and
Cellectis underscores our companies’ shared commitment to developing unique cancer therapies that may benefit patients around the world.” 

  

					
		  	 	15	  
		  			

 About Cellectis 

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART). The company’s mission is to
develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products
and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life science-focused, pioneering
genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To
find out more about us, visit our website: www.cellectis.com. 
 Talking about gene editing? We do it. 

TALEN® is a registered trademark owned by the Cellectis Group. 

About Servier 
 Servier is an independent French-based
pharmaceutical company with a strong international presence in 145 countries. It employs more than 21,000 people. 
 Its development is driven by the
pursuit of innovation in the therapeutic areas of cancer, cardiovascular, metabolic, central nervous system, psychiatric, bone, muscle and joint diseases. 

In 2014, the company recorded a turnover of 4 billion euros. 

28% of this turnover was reinvested in Research and Development. 

www.servier.com. 
 Pfizer Inc.: Working together for a
healthier worldTM 
 At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer
health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the
world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years,
Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com. 

  

					
		  	 	16	  
		  			

 PFIZER DISCLOSURE NOTICE 

The information contained in this release is as of November 19, 2015. Pfizer assumes no obligation to update forward-looking statements contained in
this release as the result of new information or future events or developments. 
 This release contains forward-looking information about UCART19
and a license and collaboration agreement between Pfizer and Servier to co-develop and commercialize UCART19, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and
completion dates as well as the possibility of unfavorable study results; whether and when drug applications may be filed in any jurisdictions for UCART19; whether and when any such applications may be approved by regulatory authorities, which will
depend on the assessment by such regulatory authorities of the benefit–risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could
affect the availability or commercial potential of UCART19; and competitive developments. 
 A further description of risks and uncertainties can be
found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information
and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.pfizer.com. 

CELLECTIS DISCLAIMER 
 This press release contains
“forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. 

This release contains forward-looking information about UCART19 and a license and collaboration agreement between Cellectis and Servier, including their
potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. 

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to
be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks and uncertainties include, but are not limited to the risk of not obtaining regulatory approval to
commence clinical trials on our UCART product candidates, the risk that our collaboration with Servier and with Pfizer will not continue or will not be successful, and the risk that any one or more product candidates will not be successfully
developed and commercialized. 
 You should read the Company’s Prospectus, including the Risk Factors set forth therein and the exhibits thereto,
completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. 

  

					
		  	 	17	  
		  			

 CONTACT:  

For Cellectis:  
 Cellectis Media:  

Jennifer Moore, 917-580-1088 
 VP Communications  

media@cellectis.com  
 or 

KCSA Strategic Communications 
 Caitlin Kasunich, 212-896-1241 

 ckasunich@kcsa.com 
 or 

Dixon Moretz, 212-896-1251  
 dmoretz@kcsa.com  

or  
 Cellectis Investor Relations: 

Simon Harnest, 646-385-9008 
 VP Finance and Investor Relations
 
 simon.harnest@cellectis.com 
 or 

For Servier:  
 Servier Communication
Department, +33 1 5572 6037  
 presse@servier.fr  

or 
 For Pfizer:  

Pfizer Media:  
 Sally Beatty, 347-330-7867 

Pfizer Global Media Relations  

Sally.Beatty@pfizer.com 
 or 

Lisa O’Neill, +44 7929 339 560 
 Pfizer Media Relations,
Europe, Middle East, Africa  
 Lisa.O’Neill@pfizer.com 

or  
 Pfizer Investor Contact:  

Ryan Crowe, 215-260-0914  
 Ryan.Crowe@pfizer.com

  

					
		  	 	18	  
		  			

 EXHIBIT C 

Development Plans 
 [***] 

 

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	19	  
	 SEPARATELY FILED WITH THE COMMISSION
	  			

 EXHIBIT D 

[***] 
  

  

					
	 [***] CONFIDENTIAL MATERIAL REDACTED AND
	  	 	20	  
	 SEPARATELY FILED WITH THE COMMISSIONEX-4.16

 Exhibit 4.16 
  

 
 CELLECTIS 

FREE SHARE 2015 PLAN 

 
  

Approved by the Board of Directors on May 18, 2015 

 TABLE OF CONTENTS 

 

					
	1.	  	IMPLEMENTATION OF THE FREE SHARE PLAN	  	1
			
	2.	  	DEFINITIONS	  	1
			
	3.	  	PURPOSE	  	2
			
	4.	  	BENEFICIARIES	  	2
			
	5.	  	NOTICE OF THE ALLOCATION OF THE SHARES	  	3
			
	6.	  	ACQUISITION PERIOD	  	3
			
		  	6.1.     Principle	  	3
			
		  	6.2     Internal mobility	  	4
			
		  	6.3     Disability	  	4
			
		  	6.4     Decease	  	4
			
		  	6.5     Retirement	  	4
			
	7.	  	HOLDING PERIOD	  	4
			
		  	7.1     Principle	  	4
			
		  	7.2     Specific situations	  	5
			
	8.	  	CHARACTERISTICS OF THE SHARES	  	5
			
	9.	  	DELIVERY AND HOLDING OF THE SHARES	  	5
			
	10.	  	INTERMEDIARY OPERATIONS	  	6
			
	11.	  	ADJUSTMENT	  	6
			
	12.	  	AMENDMENT TO THE 2015 PLAN	  	6
			
		  	12.1     Principle	  	6
			
		  	12.2     Notice of the amendments	  	7
			
	13.	  	TAX AND SOCIAL RULES	  	7
			
	14.	  	MISCELLANEOUS	  	7
			
		  	14.1     Rights in relation to the capacity of employee	  	7
			
		  	14.2     Applicable law - Jurisdiction	  	7
			
		  	14.3     Provisions Applicable to Beneficiaries Located outside of France	  	7

	1.	IMPLEMENTATION OF THE FREE SHARE PLAN 

Pursuant to decisions dated February 16, 2015, the shareholders’ general meeting of Cellectis, a French société anonyme whose
registered office is located at 8 rue de la Croix Jarry, 75013 Paris and whose identification number is 428 859 052 R.C.S. Paris (hereafter referred to as the “Company”) authorized the Board of Directors to allocate free
shares of the Company to the benefit of employees of the Company or to certain categories of such employees, and/or to the benefit of its corporate officers who meet the conditions set forth by Article L. 225-197-1 II of the French
commercial code, as well as to the benefit of employees of companies or economic interest groups whose share capital or voting rights are held, directly or indirectly, for more than ten per cent (10%) by the Company at the date of allocation of
said shares. 
 The Board of Directors decided on May 18, 2015, pursuant to the authorization of the shareholders’ general meeting dated
February 16, 2015 and after approval of the Compensation Committee, to allocate a total of 450,400 free shares of the Company to the benefit of eligible employees and approved the present free share plan stating the conditions and criteria for
the allocation of such shares (hereafter referred to as the “2015 Plan”). 
  

	2.	DEFINITIONS 

 Under the present 2015 Plan, the following terms and expressions starting
with a capital letter shall have the following meaning and may be used indifferently in the singular or in the plural form: 
  

			
	“Acquisition Date”	  	refers to the date when the free Shares have been definitely acquired by the relevant Beneficiary;
		
	“Acquisition Period”	  	refers to the two (2) year period starting on the Allocation Date and ending on the Acquisition Date, being specified that the Board of Directors may decide to extend this period so that its duration be equal to four (4) years
for certain Beneficiaries who are not French tax resident, as stated in the corresponding Allocation Letter;
		
	“Allocation”	  	refers to the decision of the Board of Directors dated May 18, 2015 to allocate free Shares to a given Beneficiary. This Allocation constitutes a right to be granted Shares at the end of the Acquisition Period subject to the
compliance with the conditions and criteria set forth by the present 2015 Plan;
		
	“Allocation Date”	  	refers to the date when the Board of Directors decided to allocate free Shares under the 2015 Plan, i.e. May 18, 2015;
		
	“Allocation Letter”	  	refers to the letter which inform a given Beneficiary of the allocation of free Shares, as stated in Article 5 of the 2015 Plan;
		
	“Beneficiaries”	  	refers to the person(s) for whose benefit the Board of Directors decided an Allocation of Shares as well as, as the case may be, his or her heirs;
		
	“Bylaws”	  	refers to the bylaws of the Company in force at the date referred to;

  
 1 

			
		
	“Disability”	  	refers to the disability of a Beneficiary corresponding to the second or third of the categories provided by Article L. 341-4 of the French social security code;
		
	“Group”	  	refers to the Company and to all the companies and groups related to the Company in the meaning of Article L. 225-197-2 of the French commercial code;
		
	“Holding Period”	  	refers to the two (2) year period starting on the Acquisition Date, being specified no Holding Period will be applicable to the Beneficiaries for whom the duration of the Acquisition Period is equal to four (4) years as from the
Allocation Date, as stated in the corresponding Allocation Letter;
		
	“Presence”	  	refers to the presence of the Beneficiary in his or her capacity of employee and/or corporate officer of the Company or of any of the companies of the Group;
		
	“Shares”	  	refers to the shares issued or which will be issued by the Company in representation of its share capital;
		
	“Trading Day”	  	refers to the working days when Euronext proceeds to the listing of shares on the Alternext market of Euronext in Paris other than days when the listings end prior to the usual closing hour.

  

	3.	PURPOSE 

 The purpose of the 2015 Plan is to set forth the conditions and
criteria for the allocation of free Shares under the 2015 Plan, pursuant to Articles L. 225-197-1 et seq. of the French commercial code and to the authorization granted by the shareholders’ general meeting of the Company dated
February 16, 2015. 
  

	4.	BENEFICIARIES 

 Pursuant to the authorization of the shareholders’
general meeting dated February 16, 2015, the Board of Directors of the Company approved the list of Beneficiaries among its employees and the employees of companies in which it holds, directly or indirectly, at least ten per cent (10%) of
the share capital and voting rights, together with the indication of the number of free Shares allocated to each of them. 

  
 2 

	5.	NOTICE OF THE ALLOCATION OF THE SHARES 

The notice of the Allocation of Shares to the Beneficiaries shall be made pursuant to an Allocation Letter sent by the Board of Directors or by
any other person selected by the Board of Directors, by registered mail with acknowledgement of receipt or delivered in person with acknowledgement of receipt, together with a copy of the present 2015 Plan, indicating the number of Shares allocated
to the Beneficiary, the Acquisition Period and the Holding Period. 
 The Beneficiary shall acknowledge receipt of the Allocation Letter and
of the 2015 Plan by sending signed copies of these documents within two (2) months from the date of receipt, the documents being deemed to be received on the first date of presentation, in the absence of which the Allocation shall be null and
void for this Beneficiary. 
 The fact that a person may benefit from the 2015 Plan does not imply that he or she shall benefit from any
other plan that may be implemented thereafter. 
  

	6.	ACQUISITION PERIOD 

  

	6.1.	Principle 

 The free Shares allocated under the 2015 Plan shall be definitively acquired
by the Beneficiaries at the end of the Acquisition Period, provided that the following condition precedent is met: 
  

	 	•	 	continued Presence of the Beneficiary during the Acquisition Period, in the absence of which he or she will not be entitled to acquire Shares on the date when this condition is no longer met; 

being specified that the Board of Directors shall be entitled to release a given Beneficiary from the condition set forth above for all or part
of the Shares granted. 
 Further, should the Beneficiary be at the same time an employee and a corporate officer of the same company or of
two companies of the Group, the loss of one of these capacities shall not result in the loss of the right to acquire the free Shares allocated under the 2015 Plan at the end of the Acquisition Period. 

Pursuant to Article L. 225-197-3 of the French commercial code, the Beneficiaries hold a claim against the Company which is personal and
may not be transferred until the end of the Acquisition Period. 
 During the Acquisition Period, the Beneficiaries will not own the free
Shares and will not be shareholders of the Company. As a consequence, they will not hold any rights attached to the Shares. 

  
 3 

	6.2	Internal mobility 

 In the event of transfer or temporary assignment of the Beneficiary
within a company of the Group, implying (i) the termination of the initial employment agreement and the entering into of a new employment agreement or of a position as corporate officer, and/or (ii) a resignation of the Beneficiary from
his or her position as corporate officer and the acceptance of a new position of corporate officer or the entering into of a new employment agreement in one of such companies, the Beneficiary shall retain his or her right to be allocated free Shares
at the end of the Acquisition Period. 
  

	6.3	Disability 

 In the event of Disability before the end of the Acquisition Period, the
free Shares shall be definitively acquired by the Beneficiary on the date of Disability. 
 For participants subject to tax in the US, the
date of such disability shall be the date such disability is incurred and in all cases such shares shall be delivered by March 15th of the year following the year in which such disability is
incurred. 
  

	6.4	Decease 

 In the event of decease of the Beneficiary during the Acquisition Period, the
free Shares shall be definitively acquired at the date of the request of allocation made by his or her beneficiaries in the framework of the inheritance. 

The request for allocation of the Shares shall be made within six (6) months from the date of the decease in compliance with Article
L. 225-197-3 of the French commercial code. 
  

	6.5	Retirement 

 In the event of the retirement of a given Beneficiary during the Acquisition
Period, the Board of Directors of the Company may decide that the condition set forth in article 6.1 above shall be deemed to be met for all or part of the Shares granted upon the date of such retirement. 

 

	7.	HOLDING PERIOD 

  

	7.1	Principle 

 During the Holding Period, if any, the Beneficiaries concerned will be the
owner of the free Shares allocated under the 2015 Plan and will be shareholders of the Company. As a consequence, they will benefit from all the rights attached to the capacity of shareholder of the Company. 

However, the free Shares shall not be available during the Holding Period and the Beneficiaries may not transfer or pledge the Shares, by any
means, or convert them into the bearer form. 
 At the end of the Holding Period, the Shares will be fully available, subject to the
provisions of the following paragraph. 

  
 4 

 At the end of the Holding Period, if the Company’s shares are listed on a regulated market,
the free Shares allocated under the 2015 Plan may not be transferred during the “black-out” periods set forth in Article L. 225-197-1 of the French commercial code, i.e., as currently provided: 

 

	 	•	 	within ten (10) Trading Days before and three (3) Trading Days after the date on which the consolidated accounts, or failing that, the annual accounts, are published; 

 

	 	•	 	during the period between the date on which the Company’s management bodies have knowledge of information which, were it to be published, could have a significant impact on the price of the Shares, and the date
falling ten (10) Trading Days after the date on which the said information is published. 

  

	7.2	Specific situations 

 Notwithstanding the provisions of the second paragraph of Article
7.1 above, the free Shares allocated to the Beneficiaries referred to at Article 6.3 above or to the beneficiaries of the deceased Beneficiary referred to at Article 6.4 above may be freely transferred as from the date of their final
allocation. 
  

	8.	CHARACTERISTICS OF THE SHARES 

The Shares definitively allocated shall be, at the Company’s choice, new ordinary shares to be issued by the Company or existing Shares
acquired by the Company. 
 As from the Acquisition Date, they shall be subject to all the provisions of the Bylaws. 

They shall be assimilated to existing ordinary shares of the Company and shall benefit from the same rights as from the Acquisition Date. 

 

	9.	DELIVERY AND HOLDING OF THE SHARES 

At the end of the Acquisition Period, the Company shall deliver to the Beneficiary the free Shares allocated under the 2015 Plan provided that
the conditions and criteria for such allocation provided by Articles 5 and 6 above are met. 
 If the Acquisition Date is not a working
day, the delivery of the Shares shall be completed the first working day following the end of the Acquisition Period. 
 The Shares that may
be acquired under the 2015 Plan will be held, during the Holding Period (if any), under the nominative form (nominatif pur) in an individual account opened in the name of the relevant Beneficiary at Société
Générale Securities Services with a mention that they cannot be transferred. At the end of the Holding Period (or the end of the Acquisition Period if there is no Holding Period), the Shares will have to remain under the nominative
form (nominatif pur) at Société Générale Securities Services until the time they are transferred to make sure that the restrictions set forth in the last paragraph of Article 7.1 above are complied with. The
conversion of the shares in another form (bearer form or nominatif administré) is not allowed under the rules of the 2015 Plan. 

  
 5 

 In the event that, as a consequence of the allocation of free Shares under the 2015 Plan, the
Company or any of the companies of the Group shall be compelled to pay taxes, social costs or any other social security taxes or contributions on behalf of the Beneficiary, the Company retains the right to postpone or to forbid the delivery of the
Shares on the Acquisition Date until the relevant Beneficiary has paid to the Company or to the relevant company of the Group the amount corresponding to these taxes, social costs, or social security taxes or contributions. 

 

	10.	INTERMEDIARY OPERATIONS 

 In the event of exchange without
equalization payment (soulte) resulting from an operation of merger or spin-off completed in compliance with the applicable regulations during the Acquisition Period or the Holding Period, the companies taking part in the operation shall
substitute to the Company and the provisions of the present 2015 Plan, and notably the durations of the Acquisition Period and of the Holding Period shall apply to the allocation rights and to the shares received in compliance with Article
L. 225-197-1 III of the French commercial code. 
 The same shall apply in the event of a public offering operation, of a division
or a grouping of shares completed in compliance with the application regulations during the Holding Period. 
  

	11.	ADJUSTMENT 

 Should the Company proceed, during the Acquisition Period, to
an amortization, to a share capital reduction, to a change in the allocation of its profits, to an allocation of free shares to all the shareholders, to a capitalization of reserves, profits or issuance premiums, to an allocation of reserves or to
an issuance of equity securities or giving right to the allocation of equity securities including a preferential subscription right reserved to the shareholders, the maximum number of Shares allocated under the 2015 Plan may be adjusted in order to
take into account said operation by application, mutatis mutandis, of the terms of adjustment provided by the law for the beneficiaries of stock options. 

Each Beneficiary shall be informed of the practical terms of the adjustment and of its consequences on the Allocation of Shares he or she
benefited from, being specified that the free Shares allocated pursuant to this adjustment shall be governed by the present 2015 Plan. 
  

	12.	AMENDMENT TO THE 2015 PLAN 

  

	12.1	Principle 

 The present 2015 Plan may be amended by the Board of Directors upon
authorization of the Supervisory Board of the Company, being specified that the amendments shall be subject to the written consent of the Beneficiaries if it results in a decrease in the rights of said Beneficiaries. 

The new provisions shall apply to the Beneficiaries of the Shares during the Acquisition Period on the date of the decision to amend the 2015
Plan taken by the Board of Directors, or the written consent of the Beneficiary, if required. 

  
 6 

	12.2	Notice of the amendments 

 The amendments to the 2015 Plan shall be notified to the
relevant Beneficiaries, by all means, including by internal mail, by simple letter or with acknowledgement of receipt, by fax or by e-mail. 
  

	13.	TAX AND SOCIAL RULES 

 The
Beneficiary shall bear all taxes and mandatory costs which he or she must bear pursuant to the applicable law in relation to the allocation of free Shares, on the due date of said taxes or costs. 

Each Beneficiary shall verify and carry out, as the case may be, the declaratory obligations he or she must comply with in relation to the
allocation of the free Shares. 
  

	14.	MISCELLANEOUS 

  

	14.1	Rights in relation to the capacity of employee 

 No provisions of the present 2015 Plan
shall be construed as granting to the Beneficiary a right to have his or her employment agreement with the Company or any of the companies of the Group maintained, or limiting the right of the Company or any of the companies of the Group to
terminate or amend the terms and conditions of the employment agreement of the Beneficiary. 
  

	14.2	Applicable law - Jurisdiction 

 The present 2015 Plan is subject to French law. Any
dispute relating to its validity, its construction or its performance shall be decided by the competent courts of the French Republic. 
  

	14.3	Provisions Applicable to Beneficiaries Located outside of France 

 The attached Appendix
applies to Beneficiaries located outside of France. 
  

Reserved to the Beneficiary: 

Mr/Ms
                             declares having read all the provisions of the 2015 Plan and Appendix, as
applicable, and expressly acknowledges that these provisions apply to him/her. 
 Made in
                         

On
                             

Signature:
                                     and initial on each page

  
 7 

 APPENDIX 

TERMS AND CONDITIONS 
 This Appendix contains
additional terms and conditions that will apply to the Beneficiary if he or she resides outside of France. Capitalized terms used but not defined herein shall have the same meanings assigned to them in the 2015 Plan. 

NOTIFICATIONS 
 This Appendix also includes
information regarding exchange control and certain other issues of which the Beneficiary should be aware with respect to his or her participation in the 2015 Plan. The information is based on the securities, exchange control and other laws in effect
in the respective countries as of May 2015. Such laws are often complex and change frequently. The Company therefore strongly recommends that the Beneficiary not rely on the information in this Appendix as the only source of information relating to
the consequences of his or her participation in the 2015 Plan because such information may be outdated when the Beneficiary vests in the Shares and/or sells any Shares issued pursuant to the award. 

GENERAL PROVISIONS 
 Taxes. Regardless of
any action the Company or Beneficiaries’ Employer (the “Employer”) takes with respect to any or all income tax, social insurance, payroll tax, or other Tax-Related withholding (“Tax-Related Items”), Beneficiary acknowledges
that the ultimate liability for all Tax-Related Items legally due by the Beneficiary is and remains Beneficiary’s responsibility and that the Company and/or the Employer (1) make no representations or undertakings regarding the treatment
of any Tax-Related Items in connection with any aspect of the Share grant, including the grant, vesting of the Shares, the subsequent sale of Shares acquired pursuant to such vesting and the receipt of any dividends; and (2) do not commit to
structure the terms of the grant or any aspect of the Shares to reduce or eliminate Beneficiary’s liability for Tax-Related Items. 
 Prior to vesting
of the Shares, Beneficiary will pay or make adequate arrangements satisfactory to the Company and/or the Employer to satisfy all withholding obligations of the Company and/or the Employer, if any. In this regard, Beneficiary authorizes the Company
and/or the Employer to withhold all applicable Tax-Related Items legally payable by Beneficiary from Beneficiary’s compensation paid to Beneficiary by the Company and/or Employer or from proceeds of the sale of Shares. Alternatively, or in
addition, if permissible under local law, the Company may (1) sell or arrange for the sale of Shares that Beneficiary acquires to meet the withholding obligation for Tax-Related Items and/or (2) withhold in Shares, provided that the
Company only withholds the amount of Shares necessary to satisfy the minimum withholding amount. Finally, Beneficiary will pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to
withhold as a result of Beneficiary’s participation in the 2015 Plan or Beneficiary’s acquisition of Shares that cannot be satisfied by the means previously described. The Company may refuse to honor the vesting and refuse to deliver the
Shares if Beneficiary fails to comply with Beneficiary’s obligations in connection with the Tax-Related Items as described in this section. 

Nature of Grant. In accepting the grant, Beneficiary acknowledges that: 

(a) the 2015 Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or
terminated by the Company at any time, unless otherwise provided in the 2015 Plan; 

  
 8 

 (b) the grant of the Shares is voluntary and occasional and does not create any contractual or
other right to receive future grants of Shares, or benefits in lieu of Shares, even if Shares have been granted repeatedly in the past; 

(c) all decisions with respect to future grants, if any, will be at the sole discretion of the Company; 

(d) Beneficiary’s participation in the 2015 Plan shall not create a right to further employment with the Employer and shall not interfere
with the ability of the Employer to terminate Beneficiary’s employment relationship at any time with or without cause unless otherwise required under local law; 

(e) Beneficiary is voluntarily participating in the 2015 Plan; 

(f) the Shares are an extraordinary item that do not constitute compensation of any kind for services of any kind rendered to the Company or
the Employer, and which is outside the scope of Beneficiary’s employment contract, if any; 
 (g) the Shares are not part of normal or
expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, long service awards, pension or retirement benefits or similar
payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company or the Employer; 

(h) in the event that Beneficiary is not an employee of the Company, the grant will not be interpreted to form an employment contract or
relationship with the Company; and furthermore, the grant will not be interpreted to form an employment contract with the Employer or any subsidiary or affiliate of the Company; 

(i) the future value of the underlying Shares is unknown and cannot be predicted with certainty; 

(j) if Beneficiary obtains Shares, the value of those Shares may increase or decrease; 

(l) in consideration of the grant, no claim or entitlement to compensation or damages shall arise from termination of the award of Shares or
diminution in value of the award resulting from termination of Beneficiary’s employment with the Company or the Employer (for any reason whatsoever) and Beneficiary irrevocably releases the Company and the Employer from any such claim that may
arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by signing the 2015 Plan, Beneficiary shall be deemed irrevocably to have waived Beneficiary’s entitlement to pursue
such claim; and 

  
 9 

 (m) unless otherwise decided by the Board of Directors, in the event of termination of
Beneficiary’s employment during the acquisition period, Beneficiary’s right to vest in the Shares under the 2015 Plan, if any, will terminate effective as of the date that Beneficiary is no longer actively employed and will not be extended
by any notice period mandated under the local law (e.g., active employment would not include a period of “garden leave” or similar period pursuant to local law). 

Data Privacy. Beneficiary hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of
Beneficiary’s personal data as described in this document by and among, as applicable, the Employer, the Company and its subsidiaries and affiliates for the exclusive purpose of implementing, administering and managing Beneficiary’s
participation in the 2015 Plan. 
 Beneficiary understands that the Company and the Employer may hold certain personal information about Beneficiary,
including, but not limited to, Beneficiary’s name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company,
details of all awards or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Beneficiary’s favor, for the exclusive purpose of implementing, administering and managing the 2015 Plan
(“Data”). 
 Beneficiary understands that the recipients of the Data may be located in France or elsewhere (including outside the European
Union), and that the recipients’ country may have different data privacy laws and protections than Beneficiary’s country. Beneficiary understands that Beneficiary may request a list with the names and addresses of any potential recipients
of the Data by contacting Beneficiary’s local human resources representative. Beneficiary authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and
managing the 2015 Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing Beneficiary’s participation in the 2015 Plan. Beneficiary understands
that Data will be held only as long as is necessary to implement, administer and manage Beneficiary’s participation in the 2015 Plan. Beneficiary understands that Beneficiary may, at any time, view the Data, request additional information about
the storage processing of the Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing Beneficiary’s local human resources representative. Beneficiary
understands, however, that refusing or withdrawing Beneficiary’s consent may affect Beneficiary’s ability to participate in the 2015 Plan. For more information on the consequences of Beneficiary’s refusal to consent or withdrawal of
consent, Beneficiary understands that Beneficiary may contact Beneficiary’s local human resources representative. 
 Language. If
Beneficiary has received this document or any other document related to the 2015 Plan translated into a language other than French and if the translated version is different than the French version, the French version will control. 

Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to the 2015 Plan or future awards that may be
granted under the 2015 Plan by electronic means or to request Beneficiary’s consent to participate in the 2015 Plan by electronic means. Beneficiary hereby consents to receive such documents by electronic delivery and, if requested, to agree to
participate in the 2015 Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. 

  
 10 

 Severability. The provisions of this 2015 Plan are severable and if any one or more provisions are
determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable. 

Country-Specific Provisions 
 United States

 Beneficiary acknowledges that both this award and any Shares are securities, the issuance by the Company of which requires compliance with federal
and state securities laws. 
 Beneficiary acknowledges that these securities are made available to Beneficiary only on the condition that Beneficiary makes
the representations contained in this section to the Company. 
 Beneficiary has made a reasonable investigation of the affairs of the Company sufficient to
be well informed as to the rights and the value of these securities. 
 The 2015 Plan has been drafted with the intent that each payment thereunder is
exempt from Internal Revenue Code Section 409A and should be interpreted accordingly. In all cases, the shares will be delivered on or before March 15th of the year following the year in
which a substantial risk of forfeiture no longer exists. 
 The Company makes no representation as to the tax status of the 2015 Plan to the
Beneficiary’s who should seek their own tax advice. 
 Term Changes/Addendum to the 2015 Plan 

Section 6.6 (Retirement) of the 2015 Plan does not apply to beneficiaries subject to tax in the United States. 

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00256-of-00352.parquet"}]]